Marcelo Losso

机构：Hospital Ramos Mejía · ORCID：0000-0002-4273-4833

发表论文 137 篇 · 总被引 5558 次 · h-index 33

代表论文

• Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (2024 · New England Journal of Medicine · 被引 261)
• Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia (2023 · JAMA · 被引 69)
• Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial (2024 · The Lancet HIV · 被引 31)
• Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19 (2024 · Clinical Infectious Diseases · 被引 16)
• Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial (2023 · The Lancet HIV · 被引 14)
• Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features (2024 · Nature Communications · 被引 12)